Beam Therapeutics (BEAM.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Event Tracking

Dec9

Wedbush Maintains Buy Rating on Beam Therapeutics

13:42

Dec8

JonesTrading analyst maintains buy rating for Beam Therapeutics with positive clinical data for sickle cell disease treatment

16:17

Dec6

Beam Therapeutics Announces Significant Efficacy in Sickle Cell Disease Clinical Trial

13:00

Capital Fund Management and other institutional investors increase holdings in Beam Therapeutics

08:55

Nov24

Evercore ISI Gives Beam Therapeutics 'Outperform' Rating

16:27

Nov11

JonesTrading analyst maintains Buy rating for Beam Therapeutics

21:16

Schedules & Filings

Schedules

Filings

Nov4

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 9.698 M, Net Income -112.73 M, EPS -1.099

Aug5

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 8.466 M, Net Income -102.29 M, EPS -1.0029

May6

Earning Release(EST)

FY2025 Q1 Earning Release (USD) Revenue 7.47 M, Net Income -109.27 M, EPS -1.242

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change